Almotriptan Malate
Loading...Almotriptan Malate Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Adults
Almotriptan Malate tablets are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura.
Adolescents Age 12 to 17 Years
Almotriptan Malate tablets are indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated).
Almotriptan Malate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with Almotriptan Malate tablets, the diagnosis of migraine should be reconsidered before Almotriptan Malate tablets are administered to treat any subsequent attacks.
In adolescents age 12 to 17 years, efficacy of Almotriptan Malate tablets on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. Almotriptan Malate tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine [see Contraindications (4.7)].
Safety and effectiveness of Almotriptan Malate tablets have not been established for cluster headache which is present in an older, predominantly male population.
History
There is currently no drug history available for this drug.
Other Information
Almotriptan Malate tablets contain almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine (±)-hydroxybutanedioate (1:1) and its structural formula is:
Its empirical formula is C17H25N3O2S-C4H6O5, representing a molecular weight of 469.56. Almotriptan is a white to slightly yellow crystalline powder that is soluble in water. Almotriptan Malate tablets for oral administration contain almotriptan malate equivalent to 6.25 or 12.5 mg of almotriptan. Each compressed tablet contains the following inactive ingredients: carnauba wax, cellulose, FD&C Blue No. 2 (12.5 mg only), hypromellose, iron oxide (6.25 mg only), mannitol, polyethylene glycol, povidone, propylene glycol, sodium starch glycolate, sodium stearyl fumarate and titanium dioxide.
Sources
Almotriptan Malate Manufacturers
-
Patriot Pharmaceuticals, Llc
![Almotriptan Malate Tablet, Coated [Patriot Pharmaceuticals, Llc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Almotriptan Malate | Patriot Pharmaceuticals, Llc
2.1 Acute Treatment of Migraine AttacksThe recommended dose of Almotriptan Malate tablets in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. As individuals may vary in their response to different doses of Almotriptan Malate tablets, the choice of dose should be made on an individual basis.
If the headache is relieved after the initial Almotriptan Malate tablets dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.
2.2 Hepatic ImpairmentThe recommended starting dose of Almotriptan Malate tablets in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)].
2.3 Renal ImpairmentThe recommended starting dose of Almotriptan Malate tablets in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)].
-
Teva Pharmaceuticals Usa Inc
Almotriptan Malate | Pfizer Animal Health
Initial Dose: 25 mg/lb (55 mg/kg) of animal body weight.
Subsequent Daily Doses: 12.5 mg/lb (27.5 mg/kg) of animal body weight.
For ease of administration in animals of varying weights, 3 tablet sizes are provided. The following table indicates how dosage may be adjusted depending on tablet size and body weight. Subsequent doses should be given at 24-hour intervals.
Tablet Size Approximate Animal Weight Initial Dose
25 mg/lb
(55 mg/kg) Subsequent Daily Doses
12.5 mg/lb
(27.5 mg/kg) 125 mg 5 lb (2.2 kg) 1 tablet 1/2 tablet 250 mg 10 lb (4.5 kg) 1 tablet 1/2 tablet 500 mg 20 lb (9.1 kg) 1 tablet 1/2 tabletTreatment may be initiated with Albon Injection 40% to obtain effective blood levels almost immediately or to facilitate treatment of the fractious animal.
Length of treatment depends on the clinical response. In most cases treatment for 3–5 days is adequate. Treatment should be continued until the animal is asymptomatic for 48 hours.
![Almotriptan Malate Tablet, Film Coated [Teva Pharmaceuticals Usa Inc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02a9444b-efd5-48b3-a107-0a0d052650d1&name=albon-tablets-3.jpg)
Login To Your Free Account